VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Control vaccine younger adults
Preclinical
A
Arcturus Therapeutics, Inc.
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[2]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Influenza, Human
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Influenza, Human
Preclinical
Completed
Clinical
Trials by Indication
[1]
Influenza, Human
1 trial
A Phase 1, First-in-human, Randomized, Observer-blind, Parallel Design, Controlled, Dose Level and Schedule-finding Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Self-Amplifying mRNA Pandemic Influenza Vaccine (ARCT-2304) When Administered to Healthy Adults
Completed
·
A
Arcturus Therapeutics, Inc.
·
Preclinical
·
NCT06602531
·
212 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for Control vaccine younger adults. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform
—
Drug–disease associations for Control vaccine younger adults. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR
—
Arcturus Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Highest Phase
Preclinical
[1]
Company
A
Arcturus Therapeutics, Inc.
Related News